Profile data is unavailable for this security.
About the company
Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development of therapies for hepatitis delta virus (HDV) and other serious diseases. Its HDV platform includes lonafarnib, an oral farnesylation inhibitor that targets a critical host process involved in viral replication. Its portfolio also includes avexitide, a well-characterized GLP-1 antagonist, as a targeted treatment for two metabolic diseases with high unmet medical needs. The avexitide is a GLP-1 antagonist for the treatment of post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism (HI). Its clinical product candidates include Lonafarnib (LNF) for HDV, Peginterferon Lambda (lambda) for HDV, Combination Therapy for HDV, Peginterferon Lambda (lambda) for COVID-19, Avexitide for Congenital Hyperinsulinism (HI) and Avexitide for Post-Bariatric Hypoglycemia (PBH). LNF is an orally bioavailable, farnesylation inhibitor that has completed a Phase 3 clinical trial for HDV infection.
- Revenue in USD (TTM)15.77m
- Net income in USD-74.96m
- Incorporated2012
- Employees25.00
- LocationEiger BioPharmaceuticals Inc2155 Park BlvdPALO ALTO 94306-1543United StatesUSA
- Phone+1 (650) 279-9845
- Fax+1 (650) 618-1621
- Websitehttps://www.eigerbio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Oncotelic Therapeutics Inc | 70.00k | -7.79m | 13.99m | 22.00 | -- | 1.18 | -- | 199.84 | -0.0197 | -0.0197 | 0.0002 | 0.0296 | 0.0021 | -- | 3.61 | 3,181.82 | -24.46 | -25.03 | -49.25 | -48.76 | -- | -- | -11,536.00 | -1,692.93 | -- | -0.4696 | 0.5341 | -- | -- | -- | -255.12 | -- | -- | -- |
| Edesa Biotech Inc | 0.00 | -7.25m | 14.09m | 16.00 | -- | 3.26 | -- | -- | -2.37 | -2.37 | 0.00 | 1.34 | 0.00 | -- | -- | 0.00 | -84.50 | -- | -107.87 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 52.28 | -- | -- | -- |
| Bullfrog AI Holdings, Inc. | 65.00k | -5.95m | 14.25m | 4.00 | -- | 2.09 | -- | 219.21 | -0.8903 | -0.8903 | 0.0097 | 0.8667 | 0.0094 | -- | -- | 16,250.00 | -85.49 | -- | -103.85 | -- | 92.00 | -- | -9,129.42 | -- | -- | -278.20 | 0.0694 | -- | 550.00 | -- | -91.11 | -- | -- | -- |
| Evaxion Biotech A/S - ADR | 124.00k | -14.69m | 14.81m | 49.00 | -- | -- | -- | 119.44 | -56.83 | -56.83 | 0.0902 | -- | -- | -- | -- | 2,530.61 | -- | -100.11 | -- | -131.65 | -- | -- | -11,846.77 | -131,560.30 | -- | -- | -- | -- | -- | -- | 4.51 | -- | 65.53 | -- |
| Cara Therapeutics Inc | 16.94m | -122.54m | 15.15m | 55.00 | -- | 0.5081 | -- | 0.8942 | -2.26 | -2.26 | 0.3118 | 0.5452 | 0.1392 | 1.34 | 4.35 | 307,963.60 | -100.70 | -35.76 | -115.83 | -40.82 | 75.18 | -- | -723.49 | -162.10 | 5.20 | -- | 0.00 | -- | -49.92 | 9.26 | -38.65 | -- | 100.66 | -- |
| KALA BIO Inc | 0.00 | -39.55m | 15.21m | 43.00 | -- | 2.28 | -- | -- | -15.15 | -15.15 | 0.00 | 2.37 | 0.00 | -- | -- | 0.00 | -63.15 | -57.83 | -76.71 | -69.32 | -- | 57.06 | -- | -1,553.61 | -- | -12.26 | 0.8382 | -- | -100.00 | -- | 5.85 | -- | -17.31 | -- |
| Eiger Biopharmaceuticals Inc | 15.77m | -74.96m | 15.24m | 25.00 | -- | -- | -- | 0.966 | -50.80 | -50.80 | 10.69 | -9.77 | 0.1985 | 0.0064 | 9.19 | 630,920.00 | -94.31 | -60.25 | -186.10 | -76.51 | 99.91 | -- | -475.26 | -823.59 | 0.6809 | -22.03 | 1.54 | -- | 16.98 | -- | 22.54 | -- | 10.51 | -- |
| Nascent Biotech Inc | 0.00 | -2.09m | 15.26m | -- | -- | 499.47 | -- | -- | -0.0147 | -0.0147 | 0.00 | 0.0002 | 0.00 | -- | -- | -- | -346.80 | -815.53 | -- | -- | -- | -- | -- | -548.75 | -- | -- | 0.8045 | -- | -100.00 | -- | -495.46 | -- | -- | -- |
| Talphera Inc | 651.00k | -14.31m | 15.79m | 15.00 | -- | 0.9667 | -- | 24.25 | -0.8945 | -0.8863 | 0.0368 | 0.9612 | 0.0237 | -- | -- | 43,400.00 | -51.96 | -22.60 | -67.70 | -28.55 | -- | -- | -2,197.39 | -714.87 | -- | -- | 0.00 | -- | -- | -21.26 | -119.16 | -- | -34.33 | -- |
| Bioxytran Inc | 0.00 | -4.30m | 16.10m | 2.00 | -- | -- | -- | -- | -0.0297 | -0.0297 | 0.00 | -0.0017 | 0.00 | -- | -- | -- | -2,431.80 | -1,420.53 | -- | -- | -- | -- | -- | -- | -- | -7.69 | -- | -- | -- | -- | -73.71 | -- | -- | -- |
| Talis Biomedical Corp | 989.00k | -57.21m | 16.14m | 99.00 | -- | 0.2848 | -- | 16.32 | -31.44 | -31.44 | 0.5434 | 31.11 | 0.0092 | -- | 14.87 | 9,989.90 | -53.08 | -68.18 | -58.71 | -74.22 | 97.27 | -- | -5,784.73 | -1,615.96 | -- | -- | 0.00 | -- | -55.65 | -2.24 | 45.13 | -- | -1.83 | -- |
| Neurosense Therapeutics Ltd | 0.00 | -11.28m | 16.20m | 16.00 | -- | -- | -- | -- | -0.7625 | -0.7625 | 0.00 | -0.1219 | 0.00 | -- | -- | 0.00 | -207.24 | -- | -395.72 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 8.59 | -- | -- | -- |
| Lyra Therapeutics Inc | 1.68m | -68.88m | 16.47m | 109.00 | -- | 0.2125 | -- | 9.81 | -1.23 | -1.23 | 0.0297 | 1.27 | 0.0143 | -- | -- | 19,090.91 | -58.52 | -58.01 | -68.02 | -68.69 | -- | -- | -4,099.82 | -6,235.31 | -- | -- | 0.00 | -- | 14.31 | 4.60 | -13.39 | -- | 95.14 | -- |
| Pharmacyte Biotech Inc | 0.00 | -14.82m | 16.48m | 2.00 | -- | 0.5296 | -- | -- | -1.64 | -1.64 | 0.00 | 5.74 | 0.00 | -- | -- | 0.00 | -1.53 | -13.35 | -1.62 | -13.70 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -1.81 | -- | -- | -- |
Data as of Jun 21 2024. Currency figures normalised to Eiger BioPharmaceuticals Inc's reporting currency: US Dollar USD
23.41%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Propel Bio Management LLCas of 31 Mar 2024 | 146.38k | 9.89% |
| Simplify Asset Management, Inc.as of 07 Jun 2024 | 90.00k | 6.08% |
| Accretive Wealth Partners LLCas of 31 Mar 2024 | 63.15k | 4.27% |
| 683 Capital Management LLCas of 31 Mar 2024 | 29.66k | 2.00% |
| RBF Capital LLCas of 31 Mar 2024 | 10.97k | 0.74% |
| Tower Research Capital LLCas of 31 Mar 2024 | 1.95k | 0.13% |
| BBVA Asset Management SA SGIICas of 31 Dec 2023 | 1.33k | 0.09% |
| Perinvest (UK) Ltd.as of 29 Sep 2023 | 1.12k | 0.08% |
| Bank of America, NA (Private Banking)as of 31 Mar 2024 | 1.06k | 0.07% |
| Pennsylvania State Employees' Retirement Systemas of 31 Dec 2021 | 1.01k | 0.07% |
More ▼
Data from 31 Dec 2021 - 31 Mar 2024Source: FactSet Research Systems Inc.
